Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company has market cap of $128.15 billion. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. It has a 15.95 P/E ratio. The companyÂ’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism ; and Erenumab for the prevention of migraine.
Tetrem Capital Management Ltd increased Thermo Fisher Scientific Inc (TMO) stake by 23.14% reported in 2017Q2 SEC filing. Tetrem Capital Management Ltd acquired 66,957 shares as Thermo Fisher Scientific Inc (TMO)’s stock rose 8.13%. The Tetrem Capital Management Ltd holds 356,341 shares with $62.17 million value, up from 289,384 last quarter. Thermo Fisher Scientific Inc now has $77.14 billion valuation. The stock increased 0.55% or $1.05 during the last trading session, reaching $192.37. About 132,118 shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 15.57% since December 14, 2016 and is uptrending. It has underperformed by 1.13% the S&P500.
Merriman Wealth Management Llc holds 7.07% of its portfolio in Amgen Inc. for 147,288 shares. Forester Capital Management Ltd owns 3,296 shares or 7.01% of their US portfolio. Moreover, Valueworks Llc has 6.57% invested in the company for 50,950 shares. The Washington-based Smead Capital Management Inc. has invested 6% in the stock. United Bank Va, a Virginia-based fund reported 28,581 shares.
Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on February, 1. They expect $3.02 EPS, up 4.50% or $0.13 from last year’s $2.89 per share. AMGN’s profit will be $2.19B for 14.61 P/E if the $3.02 EPS becomes a reality. After $3.27 actual EPS reported by Amgen Inc. for the previous quarter, Wall Street now forecasts -7.65% negative EPS growth.
The stock decreased 0.47% or $0.84 during the last trading session, reaching $176.54. About 177,312 shares traded. Amgen Inc. (AMGN) has risen 5.27% since December 14, 2016 and is uptrending. It has underperformed by 11.43% the S&P500.
Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $283,574 activity.
Investors sentiment increased to 0.96 in Q2 2017. Its up 0.05, from 0.91 in 2017Q1. It improved, as 43 investors sold TMO shares while 415 reduced holdings. 99 funds opened positions while 316 raised stakes. 323.23 million shares or 1.69% less from 328.77 million shares in 2017Q1 were reported. Counselors accumulated 63,244 shares or 0.55% of the stock. Sequoia Financial Advsr Limited Liability Company owns 1,175 shares. 2,190 were accumulated by Shapiro Capital Mngmt Limited Co. Arrow Fincl has invested 0.1% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). 9,869 are owned by Capstone Asset Mgmt. Veritas Invest Mgmt (Uk) stated it has 7.34% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Bailard Inc reported 30,865 shares stake. Grand Jean Cap Mngmt owns 111,069 shares. Kbc Grp Nv holds 0.28% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO) for 165,827 shares. Massachusetts-based Boston Family Office Ltd has invested 0.46% in Thermo Fisher Scientific Inc. (NYSE:TMO). Mcrae Cap Mgmt owns 4,484 shares or 0.32% of their US portfolio. Moreover, Qci Asset Mngmt has 0% invested in Thermo Fisher Scientific Inc. (NYSE:TMO) for 38 shares. Monroe Financial Bank & Mi has invested 0.01% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Peapack Gladstone Corporation holds 11,312 shares or 0% of its portfolio. Signaturefd Ltd Liability reported 1,192 shares.
Tetrem Capital Management Ltd decreased Crown Castle Intl Corp New (NYSE:CCI) stake by 73,610 shares to 328,869 valued at $32.95M in 2017Q2. It also reduced Dow Chem Co (NYSE:DOW) stake by 220,173 shares and now owns 773,926 shares. Unitedhealth Group Inc (NYSE:UNH) was reduced too.
Since August 2, 2017, it had 0 insider buys, and 6 insider sales for $9.13 million activity. Shares for $65,149 were sold by HARRIS C MARTIN on Wednesday, August 30. Shine Daniel P sold $366,645 worth of Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday, August 30. HORNSTRA PETER E had sold 3,894 shares worth $721,091. $1.96M worth of stock was sold by MANZI JIM P on Thursday, August 17. 30,000 shares valued at $5.28 million were sold by Herrema Gregory J. on Wednesday, August 2. On Monday, August 28 HOOGASIAN SETH H sold $736,092 worth of Thermo Fisher Scientific Inc. (NYSE:TMO) or 4,140 shares.
Among 17 analysts covering Thermo Fisher Scientific (NYSE:TMO), 16 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Thermo Fisher Scientific had 51 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, September 26 by Goldman Sachs. Leerink Swann reinitiated the stock with “Outperform” rating in Thursday, November 10 report. Leerink Swann maintained it with “Buy” rating and $187 target in Friday, April 28 report. The firm has “Overweight” rating by JP Morgan given on Thursday, September 22. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Buy” rating by Barclays Capital on Monday, September 25. Argus Research initiated it with “Buy” rating and $145 target in Tuesday, October 6 report. As per Friday, July 22, the company rating was reinitiated by BTIG Research. As per Thursday, July 23, the company rating was maintained by Mizuho. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Hold” rating given on Tuesday, June 6 by Jefferies. The firm earned “Buy” rating on Friday, September 8 by Cowen & Co.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.